secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELI LILLY & Co (LLY)
CIK:        0000059478
Form:       8-K
Filed at:   2021-08-25T23:59:59+00:00
Accession:  0000059478-21-000190
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Director Carolyn Bertozzi resigns from Lilly board due to Lycia Therapeutics collaboration
--------------------------------------------------------------------------------

- Carolyn Bertozzi resigned as independent director effective August 23, 2021, in connection with Lilly's collaboration and licensing agreement with Lycia Therapeutics.
- Bertozzi served on the board since 2017, including on Science and Technology and Ethics and Compliance committees.
- Resignation did not arise from any disagreement with Lilly's operations, policies, or practices.
- Lilly's chairman thanked Bertozzi for her service, citing her scientific expertise.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/59478/000005947821000190/0000059478-21-000190-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/59478/000005947821000190/lly-20210823.htm
  HTML page:      https://secwatch.observer/filing/0000059478-21-000190

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer